People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lucy Therapeutics, Inc. | — | Pharmaceuticals | Series B | $28.6M | $91.5M | 2023 |
Robert Michael Poole at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Michael Poole on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann DeWitt | 1 | 10 |
| Rachel Sha | 1 | 4 |
| John Ripple | 1 | 4 |
| Karoly Nikolich | 1 | 3 |
| Amy Ripka | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.